143 related articles for article (PubMed ID: 24124898)
21. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
[TBL] [Abstract][Full Text] [Related]
22. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Wurz RP; Pettus LH; Ashton K; Brown J; Chen JJ; Herberich B; Hong FT; Hu-Harrington E; Nguyen T; St Jean DJ; Tadesse S; Bauer D; Kubryk M; Zhan J; Cooke K; Mitchell P; Andrews KL; Hsieh F; Hickman D; Kalyanaraman N; Wu T; Reid DL; Lobenhofer EK; Andrews DA; Everds N; Guzman R; Parsons AT; Hedley SJ; Tedrow J; Thiel OR; Potter M; Radinsky R; Beltran PJ; Tasker AS
ACS Med Chem Lett; 2015 Sep; 6(9):987-92. PubMed ID: 26396685
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.
Zhang H; Wu W; Feng C; Liu Z; Bai E; Wang X; Lei M; Cheng H; Feng H; Shi J; Wang J; Zhang Z; Jin T; Chen S; Hu S; Zhu Y
Eur J Med Chem; 2017 Jul; 135():12-23. PubMed ID: 28426996
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
27. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
28. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
29. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.
Abd El Hadi SR; Lasheen DS; Hassan MA; Abouzid KA
Arch Pharm (Weinheim); 2016 Nov; 349(11):827-847. PubMed ID: 27734525
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
31. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors.
Mao Y; Zhu W; Kong X; Wang Z; Xie H; Ding J; Terrett NK; Shen J; Shen J
Bioorg Med Chem; 2013 Jun; 21(11):3090-104. PubMed ID: 23602524
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
[TBL] [Abstract][Full Text] [Related]
35. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
[TBL] [Abstract][Full Text] [Related]
36. A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
Xia G; Chen W; Zhang J; Shao J; Zhang Y; Huang W; Zhang L; Qi W; Sun X; Li B; Xiang Z; Ma C; Xu J; Deng H; Li Y; Li P; Miao H; Han J; Liu Y; Shen J; Yu Y
J Med Chem; 2014 Dec; 57(23):9889-900. PubMed ID: 25409491
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors.
Xun Q; Zhang Z; Luo J; Tong L; Huang M; Wang Z; Zou J; Liu Y; Xu Y; Xie H; Tu ZC; Lu X; Ding K
J Med Chem; 2018 Mar; 61(6):2353-2371. PubMed ID: 29499108
[TBL] [Abstract][Full Text] [Related]
39. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
Tsou HR; Overbeek-Klumpers EG; Hallett WA; Reich MF; Floyd MB; Johnson BD; Michalak RS; Nilakantan R; Discafani C; Golas J; Rabindran SK; Shen R; Shi X; Wang YF; Upeslacis J; Wissner A
J Med Chem; 2005 Feb; 48(4):1107-31. PubMed ID: 15715478
[TBL] [Abstract][Full Text] [Related]
40. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
Engel J; Richters A; Getlik M; Tomassi S; Keul M; Termathe M; Lategahn J; Becker C; Mayer-Wrangowski S; Grütter C; Uhlenbrock N; Krüll J; Schaumann N; Eppmann S; Kibies P; Hoffgaard F; Heil J; Menninger S; Ortiz-Cuaran S; Heuckmann JM; Tinnefeld V; Zahedi RP; Sos ML; Schultz-Fademrecht C; Thomas RK; Kast SM; Rauh D
J Med Chem; 2015 Sep; 58(17):6844-63. PubMed ID: 26275028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]